Nolan, T. Et Al. 2024. Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial.. The Lancet. Infectious diseases .

Nolan, T., Bhusal, C., Beran, J., Bloch, M., Cetin, B. S., Dinleyici, E. Ç., ... Dražan, D.(2024). Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial.. The Lancet. Infectious diseases .

Nolan, Terry Et Al. "Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial.," The Lancet. Infectious diseases , 2024

Nolan, Terry Et Al. "Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial.." The Lancet. Infectious diseases , 2024

Nolan, T. Et Al. (2024) . "Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial.." The Lancet. Infectious diseases .

@article{article, author={Terry Nolan Et Al. }, title={Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial.}, journal={The Lancet. Infectious diseases}, year=2024}